About cogent biosciences inc - COGT
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
COGT At a Glance
Cogent Biosciences, Inc.
275 Wyman Street
Waltham, Massachusetts 02451
| Phone | 1-617-945-5576 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -192,410,000.00 | |
| Sector | Health Technology | Employees | 164 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
COGT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.561 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.377 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.067 |
COGT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,173,231.707 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
COGT Liquidity
| Current Ratio | 7.094 |
| Quick Ratio | 7.094 |
| Cash Ratio | 6.962 |
COGT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -62.649 |
| Return on Equity | -74.935 |
| Return on Total Capital | -69.549 |
| Return on Invested Capital | -70.065 |
COGT Capital Structure
| Total Debt to Total Equity | 7.313 |
| Total Debt to Total Capital | 6.815 |
| Total Debt to Total Assets | 6.015 |
| Long-Term Debt to Equity | 8.832 |
| Long-Term Debt to Total Capital | 6.314 |